FORM 27

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER SECTION 85 (1) OF THE ACT

NOTE: This form is intended as a guideline. A letter or other document may be used if the substantive requirements of this form are complied with.

NOTE: Every report required to be filed under section 85 (1) of the Act shall be sent to the Commission in an envelope addressed to the Commission and marked "Continuous Disclosure."

NOTE: WHERE THIS REPORT IS FILED ON A CONFIDENTIAL BASIS PUT AT THE BEGINNING OF THE REPORT IN BLOCK CAPITALS "CONFIDENTIAL - SECTION 85" AND EVERYTHING THAT IS REQUIRED TO BE FILED SHALL BE PLACED IN AN ENVELOPE ADDRESSED TO THE SECRETARY OF THE COMMISSION MARKED "CONFIDENTIAL."

Item 1 *Reporting Issuer*
Biomax Technologies Inc.
300-1190 Hornby Street
Vancouver, BC V6Z 2K5

Item 2 *Date of Material Change*

August 29, 2000

Item 3 *Press Release*

The Issuer issued a press release on August 29, 2000 via Canadian Corporate News, a copy of which is attached.

Items 4 & 5 Summary and Full Description of Material Change
Summary: BIOMAX TECHNOLOGIES INC. ANNOUNCES CLOSING OF $2.7 MILLION OFFERING

Biomax Technologies Inc. (“Biomax,” the “Company”) is pleased to announce that it has closed the $2.7 Million offering conducted through Haywood Securities Inc., Canaccord Capital Corporation and Pacific International Securities Inc. (the “Agents”). The full offering of 6,250,000 units was fully subscribed and the Agents exercised the Over-Allotment Option and sold an additional 519,700 units. The Company issued 6,769,700 common shares at $0.40 per share and 3,384,850 non-transferable share purchase warrants for gross proceeds to the Company of $2.7 Million. Each warrant entitles the holder to acquire one common share of the Company at $0.50 and expires on August 28, 2001.

Under the terms of the Offering, the Agents received a cash commission of $230,170 (8.5% of the gross proceeds) and 750,000 Agents’ Warrants (representing 12% of the Offering). The Agents’ Warrants will expire on August 28, 2001 and each Agents’

Warrant will be exercisable into an Agents' Unit at a price of $0.50 per unit, consisting of one common share of the Company and one-half of one share purchase warrant. Each full warrant will be exercisable into one common share of the Company at an exercise price of $0.50 per share and expires on August 28, 2001.

The proceeds of the offering will be used to fund research and development, marketing and general working capital requirements.

Item 6 *Reliance on Section 85(2) of the Act*

This report is not being filed on a confidential basis.

Item 7 *Omitted Information*

Not Applicable

Item 8 *Senior Officers*

To obtain further information, contact Thomas Thompson of the Issuer at (604) 638-2770 Extension 108.

Item 9 *Statement of Senior Officer*

The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, B.C., this 29th day of August, 2000.

SIGNATURE "*Thomas Thompson*"

NAME Thomas C. Thompson

TITLE President & CEO
(must be a senior officer)

It is an offence for a person to make a statement in a document required to be filed or furnished under the Act or the Regulation that at the time and in the light of the circumstances under which it is made, is a misrepresentation.

Instructions to Complete Form 27

1. State the full name and address of the principal office in Canada of the reporting Issuer.

2. Date of Material Change

3. State the date and place(s) of issuance of the press release issued pursuant to Section 67(1) of the Act.

4. Provide a brief but accurate summary of the nature and substance of the material change.

5. Supplement the summary required under Item 4 with the disclosure which should be sufficiently complete to enable a reader to appreciate the significance of the material change without reference to other material. Management is in the best position to determine what facts are significant and must disclose those facts in a meaningful manner. See also Item 7.

   This description of the significant facts relating to the material change will therefore include some or all of the following: dates, parties, terms and conditions, description of any assets, liabilities or capital affected, purpose, financial or dollar values, reasons for the change, and a general comment on the probable impact on the reporting issuer or its subsidiaries. Specific financial forecasts would not normally be required to comply with this form.

   The above list merely describes examples of some of the facts which may be significant. The list is not intended to be inclusive or exhaustive of the information required in any particular situation.

6. If the report is being filed on a confidential basis, state reason for reliance on section 67(2) and refer to section 67(3) concerning continuing obligations in respect of reports filed pursuant to this subsection.

7. In certain circumstances where a material change has occurred and a material change report has been or is about to be filed but section 67(3) of the Act will no longer or will not be relied upon, a reporting issuer may nevertheless believe one or more significant facts otherwise required to be disclosed in the material change report should remain confidential and not be disclosed in full detail in the material change report.

   State whether any information has been omitted on this basis and provide the reasons for any such omission in sufficient detail to permit the Commission to exercise its discretion pursuant to section 169(4) of the Act.

   The reasons for the omission may be contained in a separate letter filed as provided in section 151 of the Rules.

- To facilitate any necessary follow-up by the Commission, give the name and business telephone number of a senior officer of the reporting issuer who is knowledgeable about the material change and the report or an officer through whom such senior officer may be contacted by the Commission.

BIOMAX TECHNOLOGIES INC. (BIX.CDNX)

Release No.: 2000-16	***FOR IMMEDIATE RELEASE***

BIOMAX TECHNOLOGIES INC. ANNOUNCES CLOSING OF $2.7 MILLION OFFERING

August 29, 2000 – Vancouver, BC, Canada – Biomax Technologies Inc. ("Biomax," the "Company") is pleased to announce that it has closed the $2.7 Million offering conducted through Haywood Securities Inc., Canaccord Capital Corporation and Pacific International Securities Inc. (the "Agents"). The full offering of 6,250,000 units was fully subscribed and the Agents exercised the Over-Allotment Option and sold an additional 519,700 units. The Company issued 6,769,700 common shares at $0.40 per share and 3,384,850 non-transferable share purchase warrants for gross proceeds to the Company of $2.7 Million. Each warrant entitles the holder to acquire one common share of the Company at $0.50 and expires on August 28, 2001.

Under the terms of the Offering, the Agents received a cash commission of $230,170 (8.5% of the gross proceeds) and 750,000 Agents' Warrants (representing 12% of the Offering). The Agents' Warrants will expire on August 28, 2001 and each Agents' Warrant will be exercisable into an Agents' Unit at a price of $0.50 per unit, consisting of one common share of the Company and one-half of one share purchase warrant. Each full warrant will be exercisable into one common share of the Company at an exercise price of $0.50 per share and expires on August 28, 2001.

The proceeds of the offering will be used to fund research and development, marketing and general working capital requirements.

Biomax Technologies Inc. is a Vancouver, BC-based medical device company developing optically based technologies for the treatment and diagnosis of a wide range of disease states including cancer and organ rejection. Biomax is listed on the Canadian Venture Exchange under the symbol "BIX."

On Behalf of the Board of Directors of
Biomax Technologies Inc.:

"Thomas Thompson"

Thomas C. Thompson
President & CEO

FOR MORE INFORMATION PLEASE CONTACT:
Jonathan Burke, Manager, Shareholder Communications
Tel: (604) 638-2770 Ext: 106
Thomas Thompson, President & CEO
Tel: (604) 638-2770 Ext: 108
Brian Lock, Chairman
Tel: (604) 688-7035
Email: investor@biomax.com
Web: www.biomax.com

The statements made in this press release may contain certain forward-looking comments. Actual events or results may differ from the Company's expectations. No assurances can be given that the Company will be able to complete the development of its products. In addition to the matters described in the press release, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in various countries, results of pending or future clinical trials, as well as risk factors in the Company's SEC reports, may affect the actual results achieved by the Company. Exemption from registration pursuant to Rule 12g3-2(b), File No. 0-30184.The Canadian Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.